1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Metastatic Pancreatic Cancer - Pipeline Review, H1 2016

Metastatic Pancreatic Cancer - Pipeline Review, H1 2016

  • March 2016
  • -
  • Global Markets Direct
  • -
  • 456 pages

Metastatic Pancreatic Cancer - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Metastatic Pancreatic Cancer - Pipeline Review, H1 2016’, provides an overview of the Metastatic Pancreatic Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Pancreatic Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Pancreatic Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer
- The report reviews pipeline therapeutics for Metastatic Pancreatic Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Pancreatic Cancer therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Pancreatic Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metastatic Pancreatic Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Metastatic Pancreatic Cancer - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Metastatic Pancreatic Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Metastatic Pancreatic Cancer - Overview 11
Pipeline Products for Metastatic Pancreatic Cancer - Comparative Analysis 12
Metastatic Pancreatic Cancer - Therapeutics under Development by Companies 13
Metastatic Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes 17
Metastatic Pancreatic Cancer - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Metastatic Pancreatic Cancer - Products under Development by Companies 21
Metastatic Pancreatic Cancer - Products under Investigation by Universities/Institutes 26
Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development 27
AbbVie Inc. 27
Aduro BioTech, Inc. 28
ArQule, Inc. 29
Array BioPharma Inc. 30
AstraZeneca Plc 31
Axcentua Pharmaceuticals AB 32
Berg LLC 33
Bionomics Limited 34
Boehringer Ingelheim GmbH 35
Boston Biomedical, Inc. 36
Bristol-Myers Squibb Company 37
Celgene Corporation 38
Clovis Oncology, Inc. 39
Cornerstone Pharmaceuticals, Inc. 40
CTI BioPharma Corp. 41
CytRx Corporation 42
Eleison Pharmaceuticals LLC 43
Eli Lilly and Company 44
Ensol Biosciences Inc. 45
Erytech Pharma SA 46
F. Hoffmann-La Roche Ltd. 47
Fountain Biopharma Inc. 48
Gilead Sciences, Inc. 49
GlaxoSmithKline Plc 50
HanAll Biopharma Co., Ltd. 51
Immodulon Therapeutics Ltd. 52
Incyte Corporation 53
MabVax Therapeutics Holdings, Inc. 54
Merck and Co., Inc. 55
Merrimack Pharmaceuticals, Inc. 56
Momenta Pharmaceuticals, Inc. 57
NanoCarrier Co., Ltd. 58
NantKwest, Inc. 59
Natco Pharma Limited 60
NewLink Genetics Corporation 61
Novartis AG 62
Oncolytics Biotech Inc. 63
Oncovir, Inc. 64
Oryx GmbH and Co. KG 65
Pfizer Inc. 66
Pharma Mar, S.A. 67
Pharmacyclics, Inc. 68
Phoenix Biotechnology, Inc. 69
Plexxikon Inc. 70
Precision Biologics, Inc. 71
Redx Pharma Plc 72
Rexahn Pharmaceuticals, Inc. 73
Sanofi 74
Silence Therapeutics Plc 75
Targovax AS 76
Zeria Pharmaceutical Co., Ltd. 77
Metastatic Pancreatic Cancer - Therapeutics Assessment 78
Assessment by Monotherapy Products 78
Assessment by Combination Products 79
Assessment by Target 80
Assessment by Mechanism of Action 85
Assessment by Route of Administration 89
Assessment by Molecule Type 91
Drug Profiles 93
5B1-ADC - Drug Profile 93
acalabrutinib - Drug Profile 94
aldoxorubicin hydrochloride - Drug Profile 97
alpelisib - Drug Profile 100
aNK Program - Drug Profile 102
archexin - Drug Profile 105
ARQ-761 - Drug Profile 107
asparaginase - Drug Profile 108
Atu-027 - Drug Profile 110
AXP-10711 - Drug Profile 112
bevacizumab - Drug Profile 114
BI-853520 - Drug Profile 121
binimetinib - Drug Profile 122
BNC-101 - Drug Profile 127
Cellular Immunotherapy for Oncology - Drug Profile 128
Cellular Immunotherapy to Target GM-CSFR for Pancreatic Cancer - Drug Profile 129
ceritinib - Drug Profile 131
Charis-1000 - Drug Profile 134
CIM-1 - Drug Profile 135
cisplatin - Drug Profile 136
CPI-613 - Drug Profile 138
CRS-207 - Drug Profile 140
dacomitinib - Drug Profile 143
ensituximab - Drug Profile 146
FB-704A - Drug Profile 148
galunisertib - Drug Profile 149
glufosfamide - Drug Profile 151
GS-5745 - Drug Profile 154
GSK-2256098 - Drug Profile 156
haNK Program - Drug Profile 158
HL-178 - Drug Profile 160
HuMab-5B1 - Drug Profile 161
ibrutinib - Drug Profile 162
IMM-101 - Drug Profile 170
INCB-52793 - Drug Profile 172
indoximod - Drug Profile 173
irinotecan hydrochloride - Drug Profile 176
lapatinib ditosylate - Drug Profile 179
LCL-161 - Drug Profile 183
LGK-974 - Drug Profile 185
lurbinectedin - Drug Profile 186
MesoCART - Drug Profile 190
MK-2206 - Drug Profile 191
MK-2206 + selumetinib sulfate - Drug Profile 194
MM-141 - Drug Profile 196
Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile 197
napabucasin - Drug Profile 199
necuparanib - Drug Profile 202
nimotuzumab - Drug Profile 204
NRCAN-019 - Drug Profile 208
olaparib - Drug Profile 210
paclitaxel - Drug Profile 214
paclitaxel albumin bound - Drug Profile 216
palbociclib - Drug Profile 220
Parvoryx - Drug Profile 224
PBI-05204 - Drug Profile 225
PCI-27483 - Drug Profile 227
pelareorep - Drug Profile 229
plerixafor - Drug Profile 234
PLX-7486 - Drug Profile 237
Poly-ICLC - Drug Profile 238
PRI-724 - Drug Profile 241
ribociclib - Drug Profile 243
rottlerin - Drug Profile 246
rucaparib phosphate - Drug Profile 247
SGT-53 - Drug Profile 250
Small Molecule to Inhibit Porcupine for Oncology - Drug Profile 252
Small Molecules to Inhibit Lysyl Oxidase for Metastatic Pancreatic Cancer - Drug Profile 253
sonidegib phosphate - Drug Profile 254
TG-01 - Drug Profile 258
TL-118 - Drug Profile 260
tosedostat - Drug Profile 262
trametinib dimethyl sulfoxide - Drug Profile 265
ubidecarenone - Drug Profile 268
ulixertinib - Drug Profile 270
ulocuplumab - Drug Profile 271
Vaccine for Oncology - Drug Profile 273
veliparib - Drug Profile 274
Z-360 - Drug Profile 278
Metastatic Pancreatic Cancer - Recent Pipeline Updates 280
Metastatic Pancreatic Cancer - Dormant Projects 433
Metastatic Pancreatic Cancer - Dormant Projects 433
Metastatic Pancreatic Cancer - Discontinued Products 437
Metastatic Pancreatic Cancer - Product Development Milestones 440
Featured News and Press Releases 440
Appendix 449
Methodology 449
Coverage 449
Secondary Research 449
Primary Research 449
Expert Panel Validation 449
Contact Us 449
Disclaimer 450

List of Tables
Number of Products under Development for Metastatic Pancreatic Cancer, H1 2016 17
Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H1 2016 18
Number of Products under Development by Companies, H1 2016 19
Number of Products under Development by Companies, H1 2016 (Contd..1) 20
Number of Products under Development by Companies, H1 2016 (Contd..2) 21
Number of Products under Development by Companies, H1 2016 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H1 2016 23
Comparative Analysis by Late Stage Development, H1 2016 24
Comparative Analysis by Clinical Stage Development, H1 2016 25
Comparative Analysis by Early Stage Development, H1 2016 26
Products under Development by Companies, H1 2016 27
Products under Development by Companies, H1 2016 (Contd..1) 28
Products under Development by Companies, H1 2016 (Contd..2) 29
Products under Development by Companies, H1 2016 (Contd..3) 30
Products under Development by Companies, H1 2016 (Contd..4) 31
Products under Investigation by Universities/Institutes, H1 2016 32
Metastatic Pancreatic Cancer - Pipeline by AbbVie Inc., H1 2016 33
Metastatic Pancreatic Cancer - Pipeline by Aduro BioTech, Inc., H1 2016 34
Metastatic Pancreatic Cancer - Pipeline by ArQule, Inc., H1 2016 35
Metastatic Pancreatic Cancer - Pipeline by Array BioPharma Inc., H1 2016 36
Metastatic Pancreatic Cancer - Pipeline by AstraZeneca Plc, H1 2016 37
Metastatic Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H1 2016 38
Metastatic Pancreatic Cancer - Pipeline by Berg LLC, H1 2016 39
Metastatic Pancreatic Cancer - Pipeline by Bionomics Limited, H1 2016 40
Metastatic Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 41
Metastatic Pancreatic Cancer - Pipeline by Boston Biomedical, Inc., H1 2016 42
Metastatic Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016 43
Metastatic Pancreatic Cancer - Pipeline by Celgene Corporation, H1 2016 44
Metastatic Pancreatic Cancer - Pipeline by Clovis Oncology, Inc., H1 2016 45
Metastatic Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016 46
Metastatic Pancreatic Cancer - Pipeline by CTI BioPharma Corp., H1 2016 47
Metastatic Pancreatic Cancer - Pipeline by CytRx Corporation, H1 2016 48
Metastatic Pancreatic Cancer - Pipeline by Eleison Pharmaceuticals LLC, H1 2016 49
Metastatic Pancreatic Cancer - Pipeline by Eli Lilly and Company, H1 2016 50
Metastatic Pancreatic Cancer - Pipeline by Ensol Biosciences Inc., H1 2016 51
Metastatic Pancreatic Cancer - Pipeline by Erytech Pharma SA, H1 2016 52
Metastatic Pancreatic Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 53
Metastatic Pancreatic Cancer - Pipeline by Fountain Biopharma Inc., H1 2016 54
Metastatic Pancreatic Cancer - Pipeline by Gilead Sciences, Inc., H1 2016 55
Metastatic Pancreatic Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016 56
Metastatic Pancreatic Cancer - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 57
Metastatic Pancreatic Cancer - Pipeline by Immodulon Therapeutics Ltd., H1 2016 58
Metastatic Pancreatic Cancer - Pipeline by Incyte Corporation, H1 2016 59
Metastatic Pancreatic Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2016 60
Metastatic Pancreatic Cancer - Pipeline by Merck and Co., Inc., H1 2016 61
Metastatic Pancreatic Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 62
Metastatic Pancreatic Cancer - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016 63
Metastatic Pancreatic Cancer - Pipeline by NanoCarrier Co., Ltd., H1 2016 64
Metastatic Pancreatic Cancer - Pipeline by NantKwest, Inc., H1 2016 65
Metastatic Pancreatic Cancer - Pipeline by Natco Pharma Limited, H1 2016 66
Metastatic Pancreatic Cancer - Pipeline by NewLink Genetics Corporation, H1 2016 67
Metastatic Pancreatic Cancer - Pipeline by Novartis AG, H1 2016 68
Metastatic Pancreatic Cancer - Pipeline by Oncolytics Biotech Inc., H1 2016 69
Metastatic Pancreatic Cancer - Pipeline by Oncovir, Inc., H1 2016 70
Metastatic Pancreatic Cancer - Pipeline by Oryx GmbH and Co. KG, H1 2016 71
Metastatic Pancreatic Cancer - Pipeline by Pfizer Inc., H1 2016 72
Metastatic Pancreatic Cancer - Pipeline by Pharma Mar, S.A., H1 2016 73
Metastatic Pancreatic Cancer - Pipeline by Pharmacyclics, Inc., H1 2016 74
Metastatic Pancreatic Cancer - Pipeline by Phoenix Biotechnology, Inc., H1 2016 75
Metastatic Pancreatic Cancer - Pipeline by Plexxikon Inc., H1 2016 76
Metastatic Pancreatic Cancer - Pipeline by Precision Biologics, Inc., H1 2016 77
Metastatic Pancreatic Cancer - Pipeline by Redx Pharma Plc, H1 2016 78
Metastatic Pancreatic Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016 79
Metastatic Pancreatic Cancer - Pipeline by Sanofi, H1 2016 80
Metastatic Pancreatic Cancer - Pipeline by Silence Therapeutics Plc, H1 2016 81
Metastatic Pancreatic Cancer - Pipeline by Targovax AS, H1 2016 82
Metastatic Pancreatic Cancer - Pipeline by Zeria Pharmaceutical Co., Ltd., H1 2016 83
Assessment by Monotherapy Products, H1 2016 84
Assessment by Combination Products, H1 2016 85
Number of Products by Stage and Target, H1 2016 87
Number of Products by Stage and Mechanism of Action, H1 2016 92
Number of Products by Stage and Route of Administration, H1 2016 96
Number of Products by Stage and Molecule Type, H1 2016 98
Metastatic Pancreatic Cancer Therapeutics - Recent Pipeline Updates, H1 2016 286
Metastatic Pancreatic Cancer - Dormant Projects, H1 2016 439
Metastatic Pancreatic Cancer - Dormant Projects (Contd..1), H1 2016 440
Metastatic Pancreatic Cancer - Dormant Projects (Contd..2), H1 2016 441
Metastatic Pancreatic Cancer - Dormant Projects (Contd..3), H1 2016 442
Metastatic Pancreatic Cancer - Discontinued Products, H1 2016 443
Metastatic Pancreatic Cancer - Discontinued Products (Contd..1), H1 2016 444
Metastatic Pancreatic Cancer - Discontinued Products (Contd..2), H1 2016 445

List of Figures
Number of Products under Development for Metastatic Pancreatic Cancer, H1 2016 17
Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H1 2016 18
Number of Products under Development by Companies, H1 2016 19
Number of Products under Investigation by Universities/Institutes, H1 2016 23
Comparative Analysis by Late Stage Development, H1 2016 24
Comparative Analysis by Clinical Stage Development, H1 2016 25
Comparative Analysis by Early Stage Products, H1 2016 26
Assessment by Monotherapy Products, H1 2016 84
Number of Products by Top 10 Targets, H1 2016 86
Number of Products by Stage and Top 10 Targets, H1 2016 86
Number of Products by Top 10 Mechanism of Actions, H1 2016 91
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 91
Number of Products by Top 10 Routes of Administration, H1 2016 95
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 95
Number of Products by Top 10 Molecule Types, H1 2016 97
Number of Products by Stage and Top 10 Molecule Types, H1 2016 97

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Pipeline Review, H2 2016

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) ...

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016’, provides in depth analysis ...

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Recepto ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.